102 related articles for article (PubMed ID: 9607858)
1. Cross-clade inhibition of human immunodeficiency virus type 1 primary isolates by monoclonal anti-CD4.
Shearer MH; Timanus DK; Benton PA; Lee DR; Kennedy RC
J Infect Dis; 1998 Jun; 177(6):1727-9. PubMed ID: 9607858
[TBL] [Abstract][Full Text] [Related]
2. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
3. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.
Kessler JA; McKenna PM; Emini EA; Chan CP; Patel MD; Gupta SK; Mark GE; Barbas CF; Burton DR; Conley AJ
AIDS Res Hum Retroviruses; 1997 May; 13(7):575-82. PubMed ID: 9135875
[TBL] [Abstract][Full Text] [Related]
5. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
[TBL] [Abstract][Full Text] [Related]
6. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.
Brown BK; Darden JM; Tovanabutra S; Oblander T; Frost J; Sanders-Buell E; de Souza MS; Birx DL; McCutchan FE; Polonis VR
J Virol; 2005 May; 79(10):6089-101. PubMed ID: 15857994
[TBL] [Abstract][Full Text] [Related]
7. Human erythrocytes bearing electroinserted CD4 neutralize infection in vitro by primary isolates of human immunodeficiency virus type 1.
Tosi PF; Schwartz D; Sharma U; Mouneimne Y; Hannig J; Li G; McKinley G; Grieco M; Flexner CW; Lazarte J; Norse D; Nicolau C; Volsky DJ
Blood; 1996 Jun; 87(11):4839-44. PubMed ID: 8639857
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
9. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.
Xu W; Smith-Franklin BA; Li PL; Wood C; He J; Du Q; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
J Hum Virol; 2001; 4(2):55-61. PubMed ID: 11437315
[TBL] [Abstract][Full Text] [Related]
10. Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.
Burrer R; Haessig-Einius S; Aubertin AM; Moog C
J Virol; 2003 Nov; 77(21):11385-97. PubMed ID: 14557624
[TBL] [Abstract][Full Text] [Related]
11. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.
Gorny MK; Mascola JR; Israel ZR; VanCott TC; Williams C; Balfe P; Hioe C; Brodine S; Burda S; Zolla-Pazner S
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):213-21. PubMed ID: 9491911
[TBL] [Abstract][Full Text] [Related]
12. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
Dey B; Del Castillo CS; Berger EA
J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
[TBL] [Abstract][Full Text] [Related]
14. Productive infection of CD4+ cells by selected HIV strains is not inhibited by anti-CD4 monoclonal antibodies.
Rey F; Donker G; Hirsch I; Chermann JC
Virology; 1991 Mar; 181(1):165-71. PubMed ID: 1704655
[TBL] [Abstract][Full Text] [Related]
15. The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis.
Rieber EP; Federle C; Reiter C; Krauss S; Gürtler L; Eberle J; Deinhardt F; Riethmüller G
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10792-6. PubMed ID: 1438278
[TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.
Spenlehauer C; Kirn A; Aubertin AM; Moog C
J Virol; 2001 Mar; 75(5):2235-45. PubMed ID: 11160727
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of a monoclonal antibody that inhibits HIV-1 infection.
Fu DX; Jinno A; Shimizu N; Haraguchi Y; Hoshino H
Microbes Infect; 1999 Jul; 1(9):677-84. PubMed ID: 10611745
[TBL] [Abstract][Full Text] [Related]
19. Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells.
Winters MA; Merigan TC
AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1091-6. PubMed ID: 8312052
[TBL] [Abstract][Full Text] [Related]
20. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties.
Reimann KA; Lin W; Bixler S; Browning B; Ehrenfels BN; Lucci J; Miatkowski K; Olson D; Parish TH; Rosa MD; Oleson FB; Hsu YM; Padlan EA; Letvin NL; Burkly LC
AIDS Res Hum Retroviruses; 1997 Jul; 13(11):933-43. PubMed ID: 9223409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
